Celgene (CELG): Relevance Fails, PT Drops To $147 - BMO

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Celgene (CELG): Relevance Fails, PT Drops To $147 - BMO

Celgene (CELG) PT Lowered to $130 at Stifel; 'Revlimid Plus Ritxuan did not Achieve Superiority with Co-Primary Endpoints'

December 22, 2017 8:18 AM EST

Stifel lowered its price target on Celgene (NASDAQ: CELG) to $130.00 (from $149.00) while maintaining a Buy rating, following the company's announcement regarding an update of Phase 3 trial Revlimid (Revevance).

Analyst Thomas Shrader notes a cautious outlook on the shares, commenting "that Phase III trial... More